Is evolocumab (Repatha) safe for adult patients?

Is Repatha (Evolocumab) Safe?

Yes, Repatha (evolocumab) is safe for adult patients, with an excellent long-term safety profile demonstrated over up to 8 years of continuous use, showing no increase in serious adverse events, muscle-related problems, new-onset diabetes, hemorrhagic stroke, or cognitive impairment compared to placebo. 1, 2

Safety Profile Overview

The 2022 ACC Expert Consensus provides clear guidance on evolocumab's safety 3:

Contraindications:

• History of hypersensitivity to evolocumab or any excipients

Warnings and Precautions:

• Hypersensitivity reactions (including angioedema) have occurred during clinical trials
• If serious hypersensitivity occurs, discontinue therapy immediately, treat per standard of care, and monitor until symptoms resolve
• Latex-sensitive patients should be prescribed formulations without natural rubber latex (available options exist)

Common Adverse Effects

In patients with primary hyperlipidemia (>5% incidence): 1

• Nasopharyngitis
• Upper respiratory tract infection
• Influenza
• Back pain
• Injection site reactions

In patients with established cardiovascular disease (>5% incidence): 1

• Diabetes mellitus
• Nasopharyngitis
• Upper respiratory tract infection

These adverse effects are generally mild and well-tolerated, with injection site reactions occurring in <5% of patients with very mild intensity and no cumulative effect 4.

Long-Term Safety Data

The most compelling safety evidence comes from the FOURIER trial and its open-label extension (FOURIER-OLE), which followed 6,635 patients for a median of 5 years in the extension phase, with maximum exposure to evolocumab of 8.4 years 2. This represents the longest follow-up data available for any PCSK9 inhibitor.

Key long-term safety findings:

• Incidences of serious adverse events did not exceed those in placebo-treated patients during the parent study
• No increase in muscle-related events over time
• No increase in new-onset diabetes
• No increase in hemorrhagic stroke
• No increase in neurocognitive events
• Safety profile remained stable throughout the entire follow-up period 2

Safety of Very Low LDL-C Levels

A critical safety concern has been whether achieving very low LDL cholesterol levels causes harm. The evidence is reassuring:

Cognitive Safety:

• The EBBINGHAUS substudy specifically evaluated cognitive function using validated testing (CANTAB) in 1,204 patients, showing no cognitive impairment even in patients achieving LDL-C <25 mg/dL 4
• Long-term follow-up of 473 patients for up to 7.2 years with median LDL-C of 35 mg/dL showed no change in executive function in either group 5
• No evidence of detrimental impact on steroid hormone production, bile acid circulation, or neuronal function 4

Cardiovascular Safety:

• In FOURIER, one in four patients achieved LDL-C <20 mg/dL with no safety concerns 4
• No increase in hemorrhagic stroke risk compared to statin monotherapy trials 4

Safety in Older Adults

Recent data specifically address safety in patients ≥75 years old, a population often excluded from intensive lipid-lowering due to safety concerns 6:

• Among 2,526 patients ≥75 years (median age 77) followed for median 7.1 years
• Annualized incidence rates of safety events appeared similar across treatment arms in both older and younger age groups
• No significant safety concerns emerged in this elderly population
• The number needed to treat was actually more favorable in older patients (19 vs 44 in younger patients)

Real-World Safety Experience

A Swiss multicenter observational study of 100 patients using evolocumab in real-world practice found 7:

• Treatment-emergent adverse events in 30% of patients
• Only 2 serious adverse events (in 1 patient)
• Only 3 patients discontinued due to adverse events
• 89% reported full adherence
• Safety profile similar to randomized controlled trials

Important Clinical Caveats

Pregnancy and Lactation:

• No safety data in humans; avoid use during pregnancy 1
• Patients exposed during pregnancy should be reported to Amgen's pregnancy registry
• Breastfeeding decisions should be made with healthcare provider

Latex Sensitivity:

• Some formulations contain dry natural rubber (latex derivative) in needle covers
• Latex-free formulations are available - check carton labeling 1
• The single-dose on-body infusor is not made with natural rubber latex

Muscle Symptoms:

• Interestingly, in the FOURIER trial, muscle symptoms were actually less common with evolocumab (4.7% annually) compared to standard of care with statins (8.5% annually) 4
• This makes evolocumab particularly suitable for patients with statin intolerance

Comparative Safety

While both PCSK9 inhibitors (alirocumab and evolocumab) have similar safety profiles, evolocumab has the longest safety follow-up data available (>8 years) and the largest cardiovascular outcomes trial experience 2, 8.

Bottom line: Repatha is remarkably safe with extensive long-term data supporting its use. The main contraindication is hypersensitivity, and the most common side effects are minor upper respiratory infections and injection site reactions. Concerns about very low LDL-C levels, cognitive effects, and safety in older adults have been thoroughly addressed and found to be unfounded.